186 related articles for article (PubMed ID: 12537587)
1. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
Zhang P; Gao WY; Turner S; Ducatman BS
Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
[TBL] [Abstract][Full Text] [Related]
2. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
3. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
4. [In vitro killing effects of STI571 on esophageal carcinoma cell lines CE-48T and CE-81T].
Zhang PY; Li BJ; Su XD; Wen ZS; Zhao JM; Zhang LJ; Long H; Rong TH
Ai Zheng; 2006 Apr; 25(4):456-60. PubMed ID: 16613680
[TBL] [Abstract][Full Text] [Related]
5. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
[TBL] [Abstract][Full Text] [Related]
6. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
8. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
9. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
[TBL] [Abstract][Full Text] [Related]
10. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines.
Mayorga ME; Sanchis D; Perez de Santos AM; Velasco A; Dolcet X; Casanova JM; Baradad M; Egido R; Pallares J; Espurz N; Benitez D; Mila J; Malvehy J; Castel T; Comella JX; Matias-Guiu X; Vilella R; Marti RM
Melanoma Res; 2006 Apr; 16(2):127-35. PubMed ID: 16567968
[TBL] [Abstract][Full Text] [Related]
12. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
Brama M; Basciani S; Cherubini S; Mariani S; Migliaccio S; Arizzi M; Rosano G; Spera G; Gnessi L
Endocr Relat Cancer; 2007 Mar; 14(1):61-72. PubMed ID: 17395975
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
Kawamoto T; Akisue T; Marui T; Nakatani T; Hitora T; Fujita I; Kurosaka M; Yamamoto T
Anticancer Res; 2004; 24(5A):2675-9. PubMed ID: 15517872
[TBL] [Abstract][Full Text] [Related]
14. Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
Prunotto M; Bosco M; Daniele L; Macri' L; Bonello L; Schirosi L; Rossi G; Filosso P; Mussa B; Sapino A
Lung Cancer; 2009 May; 64(2):244-6. PubMed ID: 19041155
[TBL] [Abstract][Full Text] [Related]
15. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
Altuna X; Lopez JP; Yu MA; Arandazi MJ; Harris JP; Wang-Rodriguez J; An Y; Dobrow R; Doherty JK; Ongkeko WM
Otol Neurotol; 2011 Jan; 32(1):163-70. PubMed ID: 21157293
[TBL] [Abstract][Full Text] [Related]
16. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
20. Effects of STI571 (gleevec) on pancreatic cancer cell growth.
Li J; Kleeff J; Guo J; Fischer L; Giese N; Büchler MW; Friess H
Mol Cancer; 2003 Sep; 2():32. PubMed ID: 14521721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
